In addition to panel discussions around some of the hottest topics in healthcare transformation, there is also a startup pitch contest, a presentation on government funding for startups and networking opportunities.
The conference will be held at the Ritz Carlton hotel in Chicago May 21-22. Space is limited., so secure your spot today to attend!
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Join MedCity News and nearly 300 healthcare investors, startups, and innovative-minded executives in Chicago at the Ritz Carlton on May 21-22. Space is limited. Secure your spot today to attend!
MedCity INVEST 2024, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, is the ideal event to discuss healthcare funding with investors looking for investment opportunities.
Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29!
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The conference is the premier boutique healthcare investment event in the U.S.
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
Chicago-based Rush University System for Health recently struck a partnership with Cadence — the health system is beginning an RPM pilot using the startup's technology platform and clinicians. Rush will enroll Medicare and Medicaid patients who have one or more of the following chronic conditions: hypertension, congestive heart failure and type 2 diabetes.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
CellTrans’s Lantidra is now the first FDA-approved cell therapy for type 1 diabetes. The therapy is made from islet cells sourced from deceased donors.
During the annual meeting of the American Society of Clinical Oncology, a cell therapy posted clinical data that could broaden its use in multiple myeloma. In other developments, the class of drugs called ADCs continue to make progress and a novel brain cancer drug has Phase 3 data that support its use as a new treatment option.
The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.
In a confirmatory Phase 3 test of ImmunoGen’s Elahere, the ovarian cancer drug handily beat chemotherapy with results that clinicians say could make the treatment the new standard of care for certain patients. The data were presented during the annual meeting of the American Society of Clinical Oncology.
A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.